Critical role of inflammatory mast cell in fibrosis: Potential therapeutic effect of IL-37

Cell Proliferation

Volumn 51, Issue 5, 2018, Pages

  Conti, P ^a   Caraffa, Al ^b   Mastrangelo, F ^c   Tettamanti, L ^d   Ronconi, G ^e   Frydas, I ^f   Kritas, S K ^f   Theoharides, T C ^g  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c UNIVERSITY OF FOGGIA   (Italy)

^d UNIVERSITY OF INSUBRIA   (Italy)

^e FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^f ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^g TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cytokine; fibrosis; IL 37; immunity; mast cells

Indexed keywords

INTERLEUKIN 1;

ANIMAL; FIBROBLAST; FIBROSIS; HUMAN; INFLAMMATION; MAST CELL; METABOLISM; PATHOLOGY;

ANIMALS; FIBROBLASTS; FIBROSIS; HUMANS; INFLAMMATION; INTERLEUKIN-1; MAST CELLS;

EID: 85053905309     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/cpr.12475     Document Type: Review

References (64)

1. Dinarello CA, Conti P, Mier JW. Effects of human interleukin-1 on natural killer cell activity: is fever a host defense mechanism for tumor killing? Yale J Biol Med. 1986;59:97-106.
2. Robuffo I, Toniato E, Tettamanti L, et al. Mast cell in innate immunity mediated by proinflammatory and antiinflammatory IL-1 family members. J Biol Regul Homeost Agents. 2017;31:837-842.
3. Iannitti RG, Napolioni V, Oikonomou V, et al. IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis. Nat Commun. 2016;7:10791.
4. Artlett CM. The IL-1 family of cytokines. Do they have a role in scleroderma fibrosis? Immunol Lett. 2017;195:30-37. https://doi.org/10.1016/j.imlet.2017.11.012.
5. Mack M. Inflammation and fibrosis. Matrix Biol. 2017; Nov 28. pii: S0945-053X(17)30375-X. doi: 10.1016/j.matbio.2017.11.010. [Epub ahead of print] Review. https://doi.org/10.1016/j.matbio.2017.11.010.
6. Ho CY, López B, Coelho-Filho OR, et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med. 2010;363:552-563. https://doi.org/10.1056/NEJMoa1002659.
7. Gieseck RL 3rd, Wilson MS, Wynn TA. Type 2 immunity in tissue repair and fibrosis. Nat Rev Immunol. 2018;18:62-76.
8. Hügle T. Beyond allergy: the role of mast cells in fibrosis. Swiss Med Wkly. 2014;144:w13999.
9. Chizzolini C, Brembilla NC, Montanari E, Truchetet ME. Fibrosis and immune dysregulation in systemic sclerosis. Autoimmun Rev. 2011;10:276-281.
10. Hansbro PM, Kaiko GE, Foster PS. Cytokine/anti-cytokine therapy - novel treatments for asthma? Br J Pharmacol. 2011;163:81-95.
11. Barkhordarian A, Thames AD, Du AM, et al. Viral immune surveillance: toward a TH17/TH9 gate to the central nervous system. Bioinformation. 2015;11:47-54.
12. Zhan Q, Zeng Q, Song R, et al. IL-37 suppresses MyD88-mediated inflammatory responses in human aortic valve interstitial cells. Mol Med. 2017 Mar 27;23. doi: 10.2119/molmed.2017.00022. [Epub ahead of print].
13. Viera MH, Vivas AC, Berman B. Update on Keloid management: clinical and basic science advances. Adv Wound Care (New Rochelle). 2012;1:200-206.
14. Farrell AM, Antrobus P, Simpson D, Powell S, Chapel HM, Ferry BL. A rapid flow cytometric assay to detect CD4+ and CD8+ T-helper (Th) 0, Th1 and Th2 cells in whole blood and its application to study cytokine levels in atopic dermatitis before and after cyclosporin therapy. Br J Dermatol. 2001;144:24-33.
15. Wei L. Immunological aspect of cardiac remodeling: T lymphocyte subsets in inflammation-mediated cardiac fibrosis. Exp Mol Pathol. 2011;90:74-78.
16. Qu Z, Liebler JM, Powers MR, et al. Mast cells are a major source of basic fibroblast growth factor in chronic inflammation and cutaneous hemangioma. Am J Pathol. 1995;147:564-573.
17. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res. 2004;63:423-432.
18. Galli SJ. New concepts about the mast cell. N Engl J Med. 1993;328:257-265.
19. Mukai K, Tsai M, Starkl P, Marichal T, Galli SJ. IgE and mast cells in host defense against parasites and venoms. Semin Immunopathol. 2016;38:581-603.
20. Toniato E, Frydas I, Robuffo I, et al. Activation and inhibition of adaptive immune response mediated by mast cells. J Biol Regul Homeost Agents. 2017;31:543-548. Review.
21. Aoki R, Kawamura T, Goshima F, et al. The alarmin IL-33 derived from HSV-2-infected keratinocytes triggers mast cell-mediated antiviral innate immunity. J Invest Dermatol. 2016;136:1290-1292.
22. Theoharides TC, Valent P, Akin C. Mast cells, mastocytosis, and related disorders. N Engl J Med. 2015;373:1885-1886.
23. Sismanopoulos N, Delivanis DA, Mavrommati D, Hatziagelaki E, Conti P, Theoharides TC. Do mast cells link obesity and asthma? Allergy. 2013;68:8-15.
24. Presta I, Guadagno E, Di Vito A, et al. Innate immunity may play a role in growth and relapse of chordoid meningioma. Int J Immunopathol Pharmacol. 2017;30:429-433.
25. Conti P, Caraffa AI, Kritas SK, et al. Mast cell, pro-inflammatory and anti-inflammatory: Jekyll and Hyde, the story continues. J Biol Regul Homeost Agents. 2017;31:263-267.
26. Reber LL, Hernandez JD, Galli SJ. The pathophysiology of anaphylaxis. J Allergy Clin Immunol. 2017;140:335-348.
27. Pejler G, Abrink M, Ringvall M, Wernersson S. Mast cell proteases. Adv Immunol. 2007;95:167-255.
28. Atamas SP, White B. (Cytokine regulation of pulmonary fibrosis in scleroderma. Cytokine Growth Factor Rev. 2003;14:537-550.
29. Gillitzer R, Goebeler M. Chemokines in cutaneous wound healing. J Leukoc Biol. 2001;69:513-521.
30. Gerges Geagea A, Rizzo M, Eid A, et al. Tea catechins induce crosstalk between signaling pathways and stabilize mast cells in ulcerative colitis. J Biol Regul Homeost Agents. 2017;31:865-877.
31. Landolina N, Gangwar RS, Levi-Schaffer F. Mast cells' integrated actions with eosinophils and fibroblasts in allergic inflammation: implications for therapy. Adv Immunol. 2015;125:41-85.
32. Sun Z, Chang B, Gao M, Zhang J, Zou Z. IL-33-ST2 Axis in liver disease: progression and challenge. Mediators Inflamm. 2017;2017:5314213.
33. Gangwar RS, Landolina N, Arpinati L, Levi-Schaffer F. Mast cell and eosinophil surface receptors as targets for anti-allergic therapy. Pharmacol Ther. 2017;170:37-63.
34. Lorenz G, Darisipudi MN, Anders HJ. Canonical and non-canonical effects of the NLRP3 inflammasome in kidney inflammation and fibrosis. Nephrol Dial Transplant. 2014;29:41-48.
35. Conti C, Caraffa A, Kritas SK, Ronconi G, Fulcheri M. Alexithymia and its relationships with inflammatory response mediated by IL-1 family members. J Biol Regul Homeost Agents. 2017;31:21-28.
36. Netea MG, van de Veerdonk FL, van der Meer JW, Dinarello CA, Joosten LA. Inflammasome-independent regulation of IL-1-family cytokines. Annu Rev Immunol. 2015;33:49-77.
37. Lin Q, Li Y, Zhang D, Jin H. Levels of circulating soluble receptor activator of NF-κB and interleukins-1 predicting outcome of locally advanced basal cell carcinoma. Int J Immunopathol Pharmacol. 2016;29:784-789.
38. Lonnemann G, Shapiro L, Engler-Blum G, Müller GA, Koch KM, Dinarello CA. Cytokines in human renal interstitial fibrosis. I. Interleukin-1 is a paracrine growth factor for cultured fibrosis-derived kidney fibroblasts. Kidney Int. 1995;47:837-844.
39. Rajan TS, Diomede F, Bramanti P, Trubiani O, Mazzon E. Conditioned medium from human gingival mesenchymal stem cells protects motor-neuron-like NSC-34 cells against scratch-injury-induced cell death. Int J Immunopathol Pharmacol. 2017;30:383-394.
40. Zhang H, Wu J, Dong H, Khan SA, Chu ML, Tsuda T. Fibulin-2 deficiency attenuates angiotensin II-induced cardiac hypertrophy by reducing transforming growth factor-β signalling. Clin Sci (Lond). 2014;126:275-288.
41. Theoharides TC, Petra AI, Taracanova A, Panagiotidou S, Conti P. Targeting IL-33 in autoimmunity and inflammation. J Pharmacol Exp Ther. 2015;354:24-31.
42. Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol. 2014;11:255-265.
43. Malaviya R, Ikeda T, Ross E, Abraham SN. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha. Nature. 1996;381:77-80.
44. Theoharides TC, Stewart JM, Tsilioni I. Tolerability and benefit of a tetramethoxyluteolin-containing skin lotion. Int J Immunopathol Pharmacol. 2017;30:146-151.
45. Wang X, Xu Y, Zhang Y, Si Y, Jing L, Bao H. The effect of adiponectin on LPS-induced inflammation via autophagy in RAW 264.7 macrophages. Eur J Inflamm. 2017;15:160-167.
46. Taracanova A, Alevizos M, Karagkouni A, et al. SP and IL-33 together markedly enhance TNF synthesis and secretion from human mast cells mediated by the interaction of their receptors. Proc Natl Acad Sci U S A. 2017;114:E4002-E4009.
47. Zhang S, Xie H, Wang Y, et al. Enriched environment improves behavioral performance and attenuates inflammatory response induced by TNF-α in healthy adult mice. Eur J Inflamm. 2017;15:200-209.
48. Cortez DM, Feldman MD, Mummidi S, et al. IL-17 stimulates MMP-1 expression in primary human cardiac fibroblasts via p38 MAPK- and ERK1/2-dependent C/EBP-beta, NF-kappaB, and AP-1 activation. Am J Physiol Heart Circ Physiol. 2007;293:H3356-H3365.
49. Hartmann P, Haimerl M, Mazagova M, Brenner DA, Schnabl B. Toll-like receptor 2-mediated intestinal injury and enteric tumor necrosis factor receptor I contribute to liver fibrosis in mice. Gastroenterology. 2012;143:1330-1340. e1.
50. Pérez L, Muñoz-Durango N, Riedel CA, et al. Endothelial-to-mesenchymal transition: cytokine-mediated pathways that determine endothelial fibrosis under inflammatory conditions. Cytokine Growth Factor Rev. 2017;33:41-54.
51. Aquili A, Farinelli L, Bottegoni C, Antonicelli L, Gigante A. The effect of anti-IgE therapy in knee osteoarthritis: a pilot observational study. J Biol Regul Homeost Agents. 2017;31(4 S1):1-5.
52. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity. 2013;39:1003-1018.
53. Theoharides TC, Zhang B, Kempuraj D, et al. IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc Natl Acad Sci U S A. 2010;107:4448-4453.
54. Borthwick LA. The IL-1 cytokine family and its role in inflammation and fibrosis in the lung. Semin Immunopathol. 2016;38:517-534.
55. Boesiger J, Tsai M, Maurer M, et al. Mast cells can secrete vascular permeability factor/ vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent upregulation of fc epsilon receptor I expression. J Exp Med. 1998;188:1135-1145.
56. Dinarello CA, Bufler P. Interleukin-37. Semin Immunol. 2013;25:466-468.
57. Conti P, Ronconi G, Caraffa A, Lessiani G, Duraisamy K. IL-37 a New IL-1 family member emerges as a key suppressor of asthma mediated by mast cells. Immunol Invest. 2017;46:239-250.
58. Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol. 2010;11:1014-1022.
59. Luo Y, Cai X, Liu S, et al. Suppression of antigen-specific adaptive immunity by IL-37 via induction of tolerogenic dendritic cells. Proc Natl Acad Sci U S A. 2014;111:15178-15183.
60. Kandere-Grzybowska K, Letourneau R, Kempuraj D, et al. IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells. J Immunol. 2003;171:4830-4836.
61. Huang Z, Gao C, Chi X, et al. IL-37 Expression is upregulated in patients with tuberculosis and induces macrophages towards an M2-like phenotype. Scand J Immunol. 2015;82:370-379.
62. Grabherr F, Grander C, Adolph TE, et al. Ethanol-mediated suppression of IL-37 licenses alcoholic liver disease. Liver Int. HYPERLINK \l “Liver Int. 2017 Nov 29. doi: 10.1111/liv.13642. [Epub ahead of print]. https://doi.org/10.1111/liv.13642.
63. Nakagawa S. Identification of biomarkers for tubular injury and interstitial fibrosis in chronic kidney disease. Yakugaku Zasshi. 2017;137:1355-1360. Japanese.
64. Marinari S, De Iuliis V, Dadorante V, et al. Cytokine modulation in patients with idiopathic pulmonary fibrosis undergoing treatment with steroids, immunosuppressants, and IFN-γ 1b. J Biol Regul Homeost Agents. 2017;31:59-69.